Syphilis - a disease that still occurs
DOI:
https://doi.org/10.12775/JEHS.2023.16.01.014Keywords
treatment of syphilis, penicillinAbstract
Introduction: Syphilis is a systemic disease caused by Treponema pallidum. Humans are the only hosts, and the incubation period lasts from 9-90 days. Currently it can be divided into congenital or acquired. This division is due to the moment in which the infection occurred. Congenital Syphilis- when the infection happens during the prenatal period, whereas acquired, when the infection took place in the period after birth. In early acquired syphilis the I and II stages can be distinguished as well as early latent syphilis. As defined, early latent syphilis includes an acquired infection up to 1 or 2 years back, depending on the guidelines. Late syphilis however includes: late latent syphilis, tertiary syphilis, late cardiovascular syphilis, late neurosyphilis. Congenital syphilis has also been divided into early (which includes the first 2 years) as well as late, which is characterised by signs of congenital syphilis, the so-called stigmata of congenital syphilis constituting the untreated infection during the fetal stage or the infancy stage. Aim of the Study: The aim of our study is to divert the attention to one of the sexually transmitted diseases, which despite the downward trend at the end of the 20th century, rebounded at the beginning of the 21st century, especially among men who have sexual contact with other men. We paid attention to the symptoms accompanying this disease, also in the context of congenital syphilis, as well as the different methods of pharmacological treatment according to European guidelines. Materials and methods: Reviewed literature available at scientific articles , Google Scholar using keywords: “syphilis – epidemiology”, “syphilis treatment”, “symptoms of syphilis”, as well as European guidelines regarding the treatment of syphilis.
References
European Centre for Disease Prevention and Control: http://www.ecdc.e uropa.eu/
World Health Organization: WHO guidelines for the treatment of Treponema pallidum (syphilis) 2016. <http://www.who.int/reproductivehea lth/publications/rtis/syphilis-treatment-guidelines/en>
Spiteri G., Unemo M., Moardh O., Amato-Gauci A.J.: The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe. Epidemiol. Infect., 2019; 147: e143. https://doi.org/10.1017/ S0 950 268 819 000 281
Janier M., Hegyi V., Dupin N., Unemo M., Tiplica G.S., French P, et al.: 2014 European guideline on the management of syphilis. J. Eur. Acad. Dermatol. Venereol., 2014; 20: 300-309
Grassly N.C., Fraser C., Garnett G.P.: Host immunity and synchronized epidemics of syphilis across the United Stades. Nature, 2005; 433: 417-421
Centers for Diseases Control and Prevention: Syphilis (Treponema pallidum) 2018. Case definition. CSTE 17-ID-11
Hook EW, 3rd. Syphilis. Lancet, 2017; 389: 1550-1557
Dupin N.: Syphilis. Rev. Med. Interne, 2016; 37: 735-742
Park K.H., Lee M.S., Hong I.K., et al.: Bone involvement in secondary syphilis: a case report and systematic review of the literature. Sex. Transm. Dis., 2014; 41: 532-537
Davey D.J., Kojima N., Konda K.A., et al.: Transient aortitis documented by positron emission tomography in a case series of men and transgender women infected with syphilis. Sex. Transm. Infect., 2017; 93: 551-555
Ballard R., Hook E.W. III: Syphilis. In: Unemo M., Ballard R., Ison C., Lewis D., Ndowa F., Peeling R., eds.: Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Geneva, World Health Organization (WHO). 2013: 107-129
Gayet-Ageron A., Sednaoui P., Lautenschlager S., et al.: Use of Treponema pallidum PCR in testing of ulcers for diagnosis of primary syphilis. Emerg. Infect. Dis., 2015; 21: 127-129
Muller H., Eisendle K., Brauninger W., Kutzner H., Cerroni L., Zelger B.: Comparative analysis of immuno-histochemistry, polymerase chain reaction and focus-floating microscopy for the detection of Treponema pallidum in mucocutaneous lesions of primary, secondary and tertiary syphilis. Br. J. Dermatol., 2011; 165: 50-60
Peng R.R., Wang A.L., Li J., Tucker J.D., Yin Y.P., Chen X.S.: Molecular typing of Treponema pallidum: a systematic review and meta-analysis. PLoS Negl. Trop. Dis., 2011; 5: e1273
Busse C., Navid M.H., Strubel A., Schnitzler P.: Evaluation of a new recombinant antigen-based Virotech Treponema pallidum screen ELISA for diagnosis of syphilis. Clin. Lab., 2013; 59: 523-529
Marangoni A., Nardini P., Foschi C., et al.: Evaluation of the BioPlex 2200 syphilis system as a first-line method of reverse-sequence screening for syphilis diagnosis. Clin. Vaccine Immunol., 2013; 20: 1084-1088
Sena A.C., White B., Sparling P.F.: Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin. Infect. Dis., 2010; 51: 700-708
Gliddon H.D., Peeling R., Kamb M.L., Toskin I., Wi T.E., Taylor M.M.: A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex. Transm. Infect., 2017; 93 (S4): S3-S15
Owusu-Edusei K. Jr, Gift T.L., Ballard R.C.: Cost-effectiveness of a dual non-treponemal/ treponemal syphilis point-of-care test to prevent adverse pregnancy outcome in sub-Saharan Africa. Sex. Transm. Dis., 2011; 38: 997-1003
Lukehart S.A., Hook E.W. III, Bakerzander S.A., Collier A.C., Critchlow C.W., Handsfield H.H.: Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann. Intern. Med., 1988; 109: 855-862
Davis A.P., Stern J., Tantalo L., et al.: How well do neurologic symptoms identify individuals with neurosyphilis. Clin. Infect. Dis., 2018; 66: 363-367
Marra C.M., Tantalo L.C., Maxwell C.L., Ho E.L., Sahi S.K., Jones T.: The rapid plasma reagin test cannot replace the venereal disease research laboratory test for neurosyphilis diagnosis. Sex. Transm. Dis., 2012; 39: 453-457
Shi M., Peng R.R., Gao Z., et al.: Risk profiles of neurosyphilis in HIV-negative patients with primary, secondary and latent syphilis: implications for clinical intervention. J. Eur. Acad. Dermatol. Venereol., 2016; 30: 659-666
Rolfs R.T., Joesoef M.R., Hendershot E.F., et al.: A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N. Engl. J. Med., 1997; 337: 307-314
Rolfs R.T.: Treatment of syphilis, 1993. Clin. Infect. Dis., 1995; 20 (suppl. 1): S23-38
Goh B.T., Smith G.W., Samarasinghe L., Singh V., Lim K.S.: Penicillin concentrations in serum and cerebrospinal fluid after intramuscular injection of aqueous procaine penicillin 0.6 MU with and without oral probenecid. Br. J. Venereol. Dis., 1984; 60: 371-373
Marra C.M., Boutin P., McArthur J.C., et al.: A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficiency virus-infected individuals. Clin. Infect. Dis., 2000; 30: 540-544
Dowell M.E., Ross P.G., Musher D.M., Cate T.R., Baughn R.E.: Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. Am. J. Med., 1992; 93: 481-488
Cao Y., Su X., Wang Q., et al.: A multicentre study evaluating ceftriaxone and benzathine penicillin G as treatment agents for early syphilis in Jiangsu. China. Clin. Infect. Dis., 2017; 65: 1683-1688
Amir J., Ginat S., Cohen Y.H., Marcus T.E., Keller N., Varsano I.: Lidocaine as a diluent for administration of benzathine penicillin G. Pediatr. Infect. Dis., 1998; 17: 890-893
Crowe G., Theodore C., Forster G.E., Goh B.T.: Acceptability and compliance with daily injections of procaine penicillin in the treatment of syphilis-treponemal infection. Sex. Transm. Dis., 1997; 24: 127-130
Wong T., Singh A.E., De P.: Primary syphilis treatment response to doxycycline/tetracycline versus benzathine penicillin. Am. J. Med., 2008; 121: 903-908
Boot J.M., Oranje A.P., De Groot R., Tan G., Stolz E.: Congenital syphilis. Int. J. STD AIDS, 1992; 3: 161-167
Hong F.C., Wu X.B., Yang F., et al.: Risk of congenital syphilis (CS) following treatment of maternal syphilis: results of a CS control program in China. Clin. Infect. Dis., 2017; 65: 588-594
Janier M., Chastang C., Spindler E., et al.: A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis. Dermatology, 1999; 198: 362-369
Frohlich-Knaute D., Graf N., Lautenschlager S., Weber R., Bosshard P.P.: Serological response to treatment of syphilis according to disease stage and HIV status. Clin. Infect. Dis., 2012; 55: 1615-1622
Gonzalez-Lopez J.J., Fernandez-Guerrero M.L., Lujan R., Fernandez-Tostado S., de Gorgolas M., Requena L.: Factors determining serologic response to treatment in patients with syphilis. Clin. Infect. Dis., 2009; 49: 1505-1511
Courjon J., Hubiche T., Dupin N., Grange P.A., Del Giudice P.: Clinical aspects of syphilis reinfection in HIV-infected patients. Dermatology, 2015; 230: 302-307
Ganesan A., Mesner O., Okulicz J.F., et al.: A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. Clin. Infect. Dis., 2015; 60: 653-660
Costa-Silva M., Azevedo C., Azevedo F., Lisboa C.: Early syphilis treatment in HIV-infected patients: single dose vs. three doses of benzathine penicillin G. J. Eur. Acad. Dermatol. Venereol., 2016; 10: 1805-1809
Cortes N.J., Afzali B., MacLean D., et al.: Transmission of syphilis by solid organ transplantation. Am. J. Transplant., 2006; 6: 2497-2499
Arando M., Fernandez-Naval C., Mota-Foix M., et al.: The Jarisch-Herxheimer reaction in syphilis: could molecular typing help to understand it better? J. Eur. Acad. Dermatol. Venereol., 2018; 32: 1791-1795
Traeger M.W., Schroeder S.E., Wright E.J., et al.: Effects of pre-exposure prophylaxis for the prevention of Human Immunodeficiency Virus infec- tion on sexual risk behaviour in men who have sex with men: a systematic review and meta-analysis. Clin. Infect. Dis., 2018; 67: 676-686
Grant J.S., Stafylis C., Celum C., et al.: Doxycycline prophylaxis for bacterial sexually transmitted infections. Clin. Infect. Dis., 2020; 70: 1247-1253
Katz K.A., Lee M.A., Gray T., Marcus J.L., Pierce E.F.: Repeat syphilis among men who have sex with men-San Diego county, 2004-2009. Sex. Transm. Dis., 2011; 38: 349-352
Sena A.C., Zang X.-H., Li T., et al.: A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect. Dis., 2015; 15: 479. https://doi. org/10.1186/s12 879-015-1209-0
Sena A.C., Wolff M., Behets F., et al.: Rate of decline in Nontreponemal antibody titers and seroreversion after treatment of early syphilis. Sex. Transm. Dis., 2017; 44: 6-10
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rami Ben Rhaiem, Przemysław Kępka, Daria Kuziemkowska, Jan Kuźma, Anna Łącka-Majcher, Aleksandra Łokczewska-Bojar, Grzegorz Tarsa, Magdalena Skotalczyk, Zuzanna Sawińska, Katarzyna Sudelska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 296
Number of citations: 0